Stockwinners Market Radar for August 02, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:51 EDT Pfizer: Phase 3 rivipansel study did not meet primary, key secondary endpoints - Pfizer announced that the Phase 3 Rivipansel: Evaluating Safety, Efficacy and Time to Discharge pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with intravenous opioids. The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids. "We are disappointed with the results, as we have been working in close partnership with the SCD community to advance rivipansel as a potential treatment option for acute VOC. We plan to share the study data at an upcoming scientific meeting as we want to ensure the learnings from this trial help inform future sickle cell programs that aim to improve care for SCD patients experiencing a VOC," said Brenda Cooperstone, M.D., Senior Vice President and Chief Development Officer, Rare Disease, Pfizer Global Product Development. "We express our sincere gratitude to everyone who made this study possible, including the study investigators, and in particular, the patients and their families."

18:00 EDT SPDR Gold Shares holdings rise to 830.76MT from 827.82MT - This is the highest level of holdings since June of 2018.

17:03 EDT Stabilis Energy receives Nasdaq notice of delisting for listing standard failure - Stabilis Energy announced that it received a staff determination letter from the listing qualifications department of The Nasdaq Stock Market LLC on July 30, 2019 setting forth a determination to delist the company's common stock from the Nasdaq Stock Market as a result of the company's inability to satisfy Nasdaq Listing Rule 5505a2, which requires a minimum of 1,000,000 publicly held shares, and Nasdaq Listing Rule 5505b1B, which requires a minimum market value of $15M in publicly held shares. Upon the completion of the share exchange of the company with Stabilis Energy LLC and its subsidiaries on July 26, 2019, which resulted in a change of control of the company, the company did not satisfy all of the applicable Nasdaq standards to complete the Nasdaq initial listing process. The company intends to request a hearing with a Nasdaq hearings panel to appeal the staff's delisting determination and request an extension to allow the company to meet all the applicable listing standards in accordance with a compliance plan it will present. The company intends to pursue certain actions outlined in its compliance plan to increase the number of publicly held shares as soon as practical to meet the applicable listing requirements; however, there can be no assurances that the company will be able to do so within the period of time that may be granted by the hearings panel.

16:59 EDT Crestwood Equity exec Lambert sells 30,000 common units - In a regulatory filing, Crestwood Equity Partners senior VP and general counsel Joel Christian Lambert disclosed the sale of 30,000 common units of the company at a price of $37.37 per share.

16:27 EDT Integrated Core Strategies takes 5.3% passive stake in Cytokinetics - Integrated Core Strategies disclosed a 5.3% stake in Cytokinetics, which represents over 3.07M shares. The filing does not allow for activism.

16:13 EDT Valmont CFO sells 7,500 common shares - In a regulatory filing, Valmont Industries executive VP and CFO Mark C. Jaksich disclosed the sale of 7,500 common shares of the company at a price of $137.19 per share.

15:18 EDT Loma Negra says production not affected by incident at L'Amali plant - Loma Negra informs that last Thursday night, an auxiliary building of second line of the L'Amali plant, in the city of Olavarria, which is under construction, was partially affected by a fire. "Neither casualties nor injuries were registered during the incident. Local firefighters controlled the situation in around 3 hours. The causes of the accident are yet to be determined, however no significant impacts are expected. The L'Amali Plant was not affected and operates normally serving its customers," the company stated.

14:18 EDT Trump says Ratcliffe won't be nominated as top intelligence official - U.S. President Donald Trump said via Twitter that Republican Representative John Ratcliffe has decided to stay in Congress and will not be nominated as the top U.S. intelligence official. "John has therefore decided to stay in Congress where he has done such an outstanding job representing the people of Texas, and our Country," Trump tweeted. "I will be announcing my nomination for DNI shortly." Reference Link

13:19 EDT Eli Lilly says it believes insulin pricing litigation claims 'without merit' - In a regulatory filing, Eli Lilly (LLY) said that, along with Sanofi (SNY) and Novo Nordisk (NVO), it is named as a defendant in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation, in the U.S. District Court of New Jersey relating to insulin pricing. Plaintiffs seek damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act. Separately, the company, along with Sanofi and Novo Nordisk, is named as a defendant in a purported class action lawsuit, MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In March 2019, the court dismissed, without prejudice, the plaintiffs' federal RICO Act, unjust enrichment, and certain state consumer protection law claims. Plaintiffs in that lawsuit filed a second amended complaint in April 2019 reasserting these claims. The Minnesota Attorney General's Office filed a complaint against Lilly, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court of New Jersey, alleging unjust enrichment, and violations of various Minnesota state consumer protection laws and the federal RICO Act. Additionally, the Kentucky Attorney General's Office filed a complaint against the company, Sanofi, and Novo Nordisk, Commonwealth of Kentucky v. Novo Nordisk, Inc. et al., in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. Lilly believes all of these claims are without merit and are defending against them vigorously. "We have received a subpoena from the New York Attorney General's Office and civil investigative demands from the Washington and New Mexico Attorney General Offices relating to the pricing and sale of our insulin products," Eli Lilly said in the filing. "The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We received interrogatories from the California Attorney General's Office regarding our competition in the long-acting insulin market. Finally, we received and have complied with two requests from the House of Representatives' Committee on Energy and Commerce and a request from the Senate's Committee on Health, Education, Labor, and Pensions, seeking certain information related to the pricing of insulin products, among other issues. We also received a request from the House of Representatives' Committee on Oversight and Reform and one from the Senate's Committee on Finance, both of which seek detailed commercial information and business records. We are cooperating with all of these aforementioned requests and investigations."

12:43 EDT Vistra Energy CEO says would look at taking company private to unlock value - Vistra Energy CEO, Curtis Morgan, on the company's earnings call earlier, said the company "constantly looks at what's the best way to unlock value" for the business. "I don't know if that's taking it private or not, but that will certainly be on the list." "I think he has to be," he said, adding that "We don't think that's rocket science." Shares of Vistra Energy are up 3.6% to $22.33.

12:26 EDT IBM down 2% to $147.86 after updating expectations post Red Hat deal - IBM said in investor briefing slides, "The addition of Red Hat will accelerate IBM's growth profile, expecting to add 200+ basis points of revenue growth over the next five years, through a combination of Red Hat and IBM incremental revenue. The transaction is expected to be accretive to both operating gross profit margin and free cash flow in the first year, and accretive to IBM's operating earnings per share by the end of the second year, with the near-term operating EPS dilution driven primarily by a non-cash purchase accounting adjustment."

12:00 EDT Pinterest rises 23.3% - Pinterest is up 23.3%, or $6.60 to $34.90.

12:00 EDT Aphria rises 36.8% - Aphria is up 36.8%, or $1.92 to $7.12.

11:12 EDT Chevron expects Permian to be free cash flow positive next year - Comments provided during Q2 earnings conference call.

10:47 EDT Repay Holdings says Nasdaq delisted shares in error, working on fix - Repay Holdings announced that Nasdaq has delisted its common stock "in error." The Nasdaq is "working to correct this error," Repay said in a statement.

10:31 EDT DaVita says DOJ declined to intervene in False Claims Act complaint - In a regulatory filing, DaVita noted that in January 2017, the company was served with an administrative subpoena for records by the U.S. Attorney's Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covered the period from January 1, 2007 to the present, and sought documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. "The Department of Justice notified the Court on July 23, 2019 of its decision to elect not to intervene in the matter of U.S. ex rel. David Gonzalez v. DaVita Healthcare Partners, et al. The complaint then was unsealed in the US. District Court, District of Massachusetts by order entered on August 1, 2019. The Department of Justice has confirmed that the complaint, which alleges violations of the federal False Claims Act and various state false claims acts, was the basis of its investigation initiated in January 2017. The company has not been served with the complaint," DaVita stated in the filing.

10:00 EDT Square falls -13.9% - Square is down -13.9%, or -$11.25 to $69.73.

10:00 EDT Chemours falls -18.6% - Chemours is down -18.6%, or -$3.38 to $14.78.

10:00 EDT Natural Grocers rises 18.2% - Natural Grocers is up 18.2%, or $1.67 to $10.85.

09:47 EDT Fluor falls -13.6% - Fluor is down -13.6%, or -$4.20 to $26.71.

09:47 EDT Chemours falls -17.4% - Chemours is down -17.4%, or -$3.16 to $15.00.

09:47 EDT Navigant Consulting rises 15.8% - Navigant Consulting is up 15.8%, or $3.80 to $27.84.

09:38 EDT Texas to join 13 other states in challenging T-Mobile, Sprint merger - Texas Attorney General Ken Paxton announced yesterday that Texas intends to join a coalition of 13 other states, and the District of Columbia, in challenging the proposed merger of Sprint (S) and T-Mobile (TMUS). "The merger, if consummated, would result in a substantial harm to competition in the market for mobile wireless telecommunications services, both nationwide, and specifically within the State of Texas," Paxton wrote in a statement. Reference Link

09:19 EDT Seagate sees Q1 adjusted gross margins 'roughtly flat' sequentially

09:09 EDT Seagate: Macro-related uncertainties to have NT influence on industry dynamics - Still expects to release drives over 20TB in FY20. Comments taken from Q4 earnings conference call.

09:06 EDT GeoVax Labs says will pursue 'non-traditional paths' to improve financial status - GeoVax Labs issued an update letter to its shareholders and other interested parties. In the letter, GeoVax President and CEO David Dodd addresses the recent erosion of GeoVax's common stock price and provides an update on each of the company's development programs, including its shifting focus to immuno-oncology. The letter read, in part, "In recent weeks, we have seen a severe and sharp erosion of GeoVax common stock price and resultant company valuation...The share price decline can be directly attributed to both our current capital structure, as well as our decision to move forward with a reverse stock split on May 2. Our primary intent behind seeking shareholder approval for the reverse split was to position the Company for listing on Nasdaq in conjunction with a significant financing event, with the expectation that subsequent events would support a higher stock valuation. For various reasons, these plans did not materialize in the way we had hoped. Unfortunately, we were then compelled to execute the reverse split due both to our need for increased authorized shares in support of continued capital development, including the need for available shares to support the sale of securities to our primary investors, to keep the Company operational, as well as to meet the minimum stock price required to maintain our listing on the OTC Market. Our primary investors often convert their preferred shares into common stock, or exercise their warrants to purchase our common stock, and sell those shares. Our dire need for additional authorized shares was such that we had no other alternative but to proceed with the reverse split. Most disappointingly, our share price immediately collapsed, eliminating our ability to proceed with the steps to achieve the "Nasdaq uplisting". ..While our financial status may be disheartening, we believe the promise of our technology and development programs continues to be impressive. But the reality is, GeoVax remains highly undercapitalized, and we have been unable to advance any of our promising non-HIV development programs into the critical realm of human clinical trials. We continue to seek strategic collaborations or partnerships with other companies that may result in funding arrangements which would reduce our need for additional equity capital or lead to such arrangements. While we have engaged in various such discussions, virtually all such funding agreements are predicated on our having advanced the respective product into clinical development. In most discussions, we consistently receive highly positive and complimentary comments regarding the validation of our technology and expertise. Unfortunately, without having the requisite human clinical data, no potential collaborator or partner has been willing to proceed to a definitive agreement. This is the "Catch-22" in which we find ourselves... needing the human clinical data to support further corporate development and funding, but not having adequate financial resources to generate the data...In summary, to achieve material improvement in GeoVax's financial status, we will have to successfully pursue non-traditional paths, outside of traditional financing and capital development. We all are disappointed in the current financial status of the Company. Regardless, our primary commitment is to identify a path to achieving clinical development within our strategic area of focus, immuno-oncology. We believe that this can lead to a significantly improved company valuation, providing the basis for continued progress."

09:01 EDT Delta Air Lines reports July traffic up 5.2%, capacity up 3.5% - Reports load factor up 1.4 pts to 90.0%.

08:49 EDT Synchronoss appoints Laurie Harris to board of directors - Synchronoss Technologies announced that Laurie Harris has been elected to the Synchronoss Board of Directors and will serve as Audit Chair. Harris, who has an extensive background in the financial services industry for more than 30 years, most recently served as a global engagement audit partner with PricewaterhouseCoopers.

08:37 EDT Weyland Tech engages CMA to lead strategic investor, public relations program - Weyland Tech has engaged CMA to lead a new strategic investor and public relations program. CMA will work closely with Weyland management to develop and execute a comprehensive capital markets strategy. The company will receive access to CMA's proprietary network of high-net worth investors, equity analysts, institutional investors, investment bankers, media and other valuable market resources. Activities will include strategic advisory, investor and media communications, and introductions to key market players in the U.S., Canada and internationally. CMA will also schedule meetings and investor conferences for management over the next several months.

08:32 EDT Francesca's adopts stockholder rights plan - Francesca's Holdings Corporation announced that its Board of Directors unanimously adopted a Rights Agreement and declared a dividend of one preferred share purchase right on each outstanding share of the Company's common stock, par value 1c per share following the Board's evaluation and consultation with the Company's advisors. The Board adopted the Rights Plan to deter any entity, person or group from gaining control of the Company through the open market or private transactions without paying an appropriate control premium or offering fair and adequate value to all stockholders. It is intended to enable the stockholders of the Company to realize the value of their investment in the Company, ensure that all stockholders receive fair treatment, and provide the Board and stockholders with adequate time to make informed decisions. The Rights Plan is not intended to deter offers that are fair and otherwise in the best interests of the Company's stockholders. In the event the Rights become exercisable, each Right will initially entitle stockholders to buy one five-thousandth of a share of Series A Junior Participating Preferred Stock, par value 1c per share, of the Company at an exercise price of $18.00 per one five-thousandth of a share of Preferred Stock, subject to adjustment and the terms of the Rights Plan. In general, the Rights will become exercisable ten business days after a person or group becomes the beneficial owner of 15% or more of the outstanding Common Stock or announces a tender offer for 15% or more of the outstanding Common Stock. The Board of Directors will in general be entitled to redeem the Rights, in whole but not in part, at 0.1c per Right at any time before the triggering ownership threshold is crossed. In the event that the Rights become exercisable due to the triggering ownership threshold being crossed, each Right will entitle its holder to purchase, at the Right's exercise price, a number of shares of Common Stock, in lieu of shares of Preferred Stock, with an aggregate value equal to twice the Right's exercise price. Rights held by the triggering person will become void and will not be exercisable to purchase shares at the reduced purchase price. After the Rights have become exercisable, the Board of Directors may also choose to exchange the Rights, in whole or in part, for shares of Common Stock or Preferred Stock at an exchange ratio of one share of Common Stock or a fractional share of Preferred Stock per Right. Further details about the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission. The dividend distribution will be payable on August 29, 2019, to stockholders of record as of the close of business on August 15, 2019. The Rights will expire at the close of business on August 1, 2022, unless the Rights are earlier redeemed or exchanged by the Company. The Rights distribution is not taxable to stockholders.

08:25 EDT BlueLinx announces distribution of Allura products in Maryland, Florida - BlueLinx Holdings announced that it is now distributing Allura fiber cement products from its distribution centers in Frederick, Maryland and Jacksonville, Lakeland, Miami, Pensacola, and Tampa, Florida.

08:21 EDT Arbor Realty raises quarterly dividend 4% to 29c per share - The Company announced today that its Board of Directors has declared a quarterly cash dividend of 29c per share of common stock for the quarter ended June 30, 2019, representing an increase of 4% over the prior quarter dividend of 28c per share and 16% from a year ago. The dividend is payable on September 3, 2019 to common stockholders of record on August 15, 2019. The ex-dividend date is August 14, 2019.

08:19 EDT Sprint reports Q1 postpaid churn of 1.74% - Reports Q1 postpaid phone churn of 1.78%, prepaid 4.23%.

08:15 EDT Waste Connections names Elise Jordan to board of directors - Waste Connections (WCN) announced that Elise Jordan has been appointed to its Board of Directors. Jordan is Executive Vice President and CFO of FedEx Express, the largest transportation company in the FedEx Corp. (FDX) enterprise.

08:10 EDT Regional Health Properties sells three properties for $26.1M - Regional Health Properties has completed the sale of three of the four skilled nursing properties located in Oklahoma, Alabama and Georgia, to affiliates of MED Healthcare Partners, as contemplated by the purchase and sale agreement previously disclosed by the company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 18. The three properties were sold for the purchase price of $26.1M in cash. The company and MED agreed to extend the closing date on the fourth property located in Oklahoma to August 28. The company used the cash proceeds from the sale to pay a net of approximately $1.0M in outstanding interest, fees, and other costs and to repay $24.7M in debt. As a result of such repayment, the company has extinguished all debt owing to Pinecone Realty Partners II and Congressional Bank.

08:07 EDT Sprint CEO says 'the business still faces several structural headwinds' - "While we delivered good results in the first quarter relative to expectations, the business still faces several structural headwinds and I remain convinced the merger with T-Mobile is the best outcome for our customers, employees, industry and all stakeholders," said Sprint CEO Michel Combes. "With the recent clearance of our merger by the Department of Justice, and the anticipated approval from the FCC, we are moving one step closer to building one of the world's most advanced 5G networks and providing American consumers a better network and overall experience at New T-Mobile."

08:05 EDT Sprint reports continued momentum on Next-Gen network deployment - True Mobile 5G network launched in parts of five major metro areas with more to come. Network investments of $1.2B grew year-over-year for the fourth consecutive quarter. Further progress on digitalization initiatives. Postpaid gross additions in digital channels increased approximately 50% year-over-year.

08:04 EDT Sprint reports Q1 wireless service revenue of $5.3B - Postpaid wireless service revenue of $4.2B grew year-over-year. Postpaid average revenue per account of $124.89 stabilized year-over-year.

08:03 EDT Sprint reports Q1 postpaid net additions of 134,000 - Data device net additions of 262,000 were partially offset by phone net losses of 128,000. Average postpaid accounts were stable year-over-year.

07:53 EDT Stemline institutes Early Access Program for ELZONRIS - Stemline has instituted a global Early Access Program whereby physicians may seek access to ELZONRIS outside of a clinical trial and/or before it is commercially available.

07:51 EDT Stemline evaluating ELZONRIS combinations in Phase 1/2 trial of AML - The company said, "ELZONRIS in combination with other agents is currently being evaluated in an investigator-sponsored Phase 1/2 trial of patients with AML and high-risk myelodysplastic syndrome. Additional investigator-sponsored trials of ELZONRIS in combination with other agents in patients with subsets of AML that are enriched for CD123+ and/or BPDCN-like features are targeted to open in the 4Q19/1H20 timeframe. Other indications are also under consideration. "

07:48 EDT Stemline plans to open addition cohort in Phase 2 trial of ELZONRIS in CMML - The company said, "ELZONRIS clinical data from its ongoing Phase 2 clinical trial in patients with CMML were presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago, Illinois and at the 24th Congress of the European Hematology Association in Amsterdam, Netherlands. We plan to open an additional single-arm cohort, Stage 3, of patients with previously-treated CMML to the currently enrolling trial later this year. In the first part of Stage 3, enrichment strategies and certain efficacy endpoints, including spleen size reduction and bone marrow complete response with partial hematologic recovery, will be assessed for potential inclusion in the confirmatory cohort, that will aim to provide the primary evidence of efficacy to support potential registration."

07:44 EDT Chart Industries serves as key supplier for Nitro beverages - The company said, "Chart Industries is pleased to be a key supplier for liquid nitrogen dosing products in food & beverage nitro beverages. Today, August 2nd, Starbucks (SBUX) is giving out free Nitro Cold Brew at stores across the United States. The in-store shots are from compressed nitrogen gas; our liquid nitrogen dosing is used in another Starbucks product, Double Shot Coffee, which is sold and served in aluminum cans. Liquid nitrogen dosing adds pressure in the can for the packaging process."

07:42 EDT Exxon Mobil says Q1 average crude prices stronger than Q1 - In its Upstream business, Exxon Mobil said Q2 average crude prices were stronger than Q1, while natural gas prices declined with supply length and crude-linked LNG lag effects. Liquids volumes increased with unconventional growth and ramp-up at Hebron, partly offset by the impacts of higher planned maintenance. Natural gas volumes were down from the first quarter due to weaker seasonal gas demand in Europe. Permian unconventional development continued with production up over 20 percent from the first quarter and up nearly 90 percent from Q2 of last year. In Downstream, Exxon Mobil said industry fuels margins, while remaining under pressure during the second quarter, improved from very low levels in the first quarter on stronger gasoline margins, mainly in the U.S. Planned maintenance activity remained at a high level during the quarter, as the company successfully completed a significant turnaround at its Joliet, Illinois, refinery in the U.S. mid-continent region. Results were also impacted by unscheduled downtime at refineries in Baytown, Texas; Sarnia (Canada); and Yanbu (Saudi Arabia). In the Chemical business, Paraxylene margins weakened during the quarter with lengthening supply from recent industry capacity additions. Results were impacted by a significant increase in turnaround activity during the second quarter. Production at the new ethane steam cracker in Baytown, Texas, successfully increased to exceed design capacity by 10 percent.

07:40 EDT Cronos Group to acquire four Redwood Holding subsidiaries for $300M - Cronos Group announced that it has entered into a definitive agreement to acquire four of Redwood Holding Group, LLC's operating subsidiaries. Redwood manufactures, markets and distributes hemp-derived cannabidiol infused skincare and other consumer products online and through retail and hospitality partner channels in the United States under the brand, Lord Jones. Redwood's products use pure hemp oil that contains natural phytocannabinoids and terpenes found in the plant. Redwood was co-founded in 2017 by Robert Rosenheck and Cindy Capobianco. Following the close of the transaction, Mr. Rosenheck and Ms. Capobianco will join Cronos Group and continue to lead the development of the Redwood platform with the support of the current team, brand names and operating locations remaining in place. Under the terms of the agreement, Cronos Group will acquire Redwood for approximately $300M, net of Redwood's estimated cash and debt and subject to a customary working capital adjustment as described in the agreement. $225M of the total consideration will be paid in cash with the balance paid in newly issued Cronos Group common shares. Cronos Group will fund the cash portion of the transaction with cash on hand. The transaction is expected to close in the third quarter of 2019, subject to customary closing conditions and regulatory approvals.

07:36 EDT LyondellBasell says A. Schulman integration activities on schedule - Integration activities related to the acquisition of A. Schulman are on schedule and expected to generate approximately $100M in forward annual run-rate synergies as of the close of Q2.

07:35 EDT Harrow Health subsidiary to acquire worldwide rights to Zian molecule - Harrow Health announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian anti-microbial molecule for ophthalmic and otic uses. Zian is a patented small molecule that is water soluble, colorless and odorless, and was developed to treat various complex bacterial, fungal, and viral infections, including in the eye and ear. The initial primary indication for Stowe's initial drug candidates is expected to be adenoviral conjunctivitis, with secondary indications for mixed bacterial-viral infections, keratitis, endophthalmitis, and corneal ulcers.

07:29 EDT Momenta to cease active development of M923 - Momenta announced the Company will cease active development of M923 at this time, due to changes in the market opportunity associated with Humira patent litigation settlements.

07:28 EDT Momenta expects to report data from Phase 1/2 study of M254 in 1H20 - The Company's Phase 1/2 clinical trial in idiopathic thrombocytopenic purpura is progressing. The multi-part study has completed Part A, which evaluated M254 in a single ascending dose cohort of healthy volunteers, and has advanced into Part B, which will evaluate M254 in a SAD cohort of ITP patients. Parts C and D include a randomized cross-over study comparing M254 to IVIg and a multiple ascending dose study of M254, respectively. Enrollment for this trial is ongoing and the Company expects to report preliminary data from this study in the first half of 2020.

07:26 EDT Momenta expects to report data from Phase 2 study of nipocalimab in 2020 - Vivacity-MG, the Company's Phase 2 clinical study of nipocalimab in generalized myasthenia gravis, continues to open sites and enroll patients and the Company expects to report top-line data in the second or third quarter of 2020.

07:23 EDT Amicus receives marketing authorization for Galafold in Argentina - Amicus Therapeutics announced that the Agency of Medicines, Food and Medical Devices in Argentina has granted approval for the first-in-class, oral small molecule pharmacological chaperone Galafold, as a monotherapy for the treatment of people aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. Galafold is an oral precision medicine for Fabry disease approved in Argentina. Amicus is working with a local partner, Pint Pharma, to complete the requirements to launch Galafold in the coming months. Argentina represents the first approval for Galafold in Latin America. Additional submissions for marketing authorizations are under review or planned in this important region. The Argentinian label for Galafold includes over 350 GLA mutations that have been identified and determined to be amenable based on the Galafold Amenability Assay. It is estimated that between 35% and 50% of people diagnosed with Fabry disease may have an amenable GLA mutation. In addition to Argentina, Galafold is approved in Australia, Canada, the European Union, Israel, Japan, South Korea, Switzerland and the U.S.

07:18 EDT Enbridge to hold open season for transportation services on Canadian Mainline - Enbridge announced it will be holding an open season for transportation services on the Canadian Mainline pipeline system. The Canadian Mainline is a common carrier pipeline system with 100% of its transportation capacity currently available to shippers on a spot, or uncommitted, basis. The competitive tolling settlement, or CTS, that governs transportation tolls on the Mainline will expire on June 30, 2021. In advance of CTS expiration, Enbridge has spent considerable time negotiating with its shippers and is holding an open season in order to provide shippers with the opportunity to enter into long-term contracts for priority transportation service on the Canadian Mainline, with at least 10% of capacity reserved for uncommitted volumes at all times. The open season offering includes priority access in Canada for contracted volume, contract term up to 20 years and toll discounts for longer terms and higher volumes. Enbridge is seeking to have Canadian Mainline contracting take effect on July 1, 2021, subject to regulatory approval. Following completion of the Line 3 Replacement project, Mainline capacity will be 3.225 Mbpd, of which up to 2.9 Mbpd will be contracted with the remaining 325 kbpd remaining in spot service.

07:04 EDT Momenta sees available funds taking company beyond clinical read outs in 2020 - "In connection with the recent Amphastar (AMPH) settlement and our contractual obligations to GSK (GSK), we incurred one-time operating expenses in the second quarter. Importantly, as these charges are also connected with long-term cost-savings, these charges do not impact our forecasted cash runway and we continue to expect our available funds will take us beyond our clinical read outs in 2020," said Michelle Robertson, Chief Financial Officer at Momenta Pharmaceuticals (MNTA).

06:55 EDT Seadrill Partners receives early termination notice for West Vencedor - Seadrill Partners has received an early termination notice for the West Vencedor contract offshore Cote d'Ivoire prior to its commencement which was expected in Q3. The unit had recently completed its work in Myanmar and will now stay in Southeast Asia to be marketed for additional opportunities. Seadrill Partners is expected to receive a lump sum early termination payment in Q3 of approximately the amount of adjusted EBITDA that would have been earned under the firm term of the contract and backlog will decrease by $20M.

06:52 EDT Noble Energy anticipates Q3 volumes 370-385 MBoe/d - Sees Q3 CapEx view to $600M-$675M. Unit production expenses continue to trend favorably with full-year guidance lowered 15c per BOE. All three U.S. onshore basins are expected to deliver higher third quarter 2019 volumes sequentially as a result of the count and timing of wells that began production during the second quarter. At the mid-point of guidance, U.S. onshore oil volumes are expected to increase 10 MBbl/d. Internationally, Q3 sales volumes are also anticipated to be higher, benefiting from the timing of liquids liftings in West Africa and seasonal demand in Israel.

06:39 EDT Newell Brands CEO says Q2 represents 'another quarter of progress' - "The financial results we announced this morning represent another quarter of progress, with disciplined cost management and focused execution behind working capital initiatives driving better than expected margin and cash flow progression in the second quarter," said Chris Peterson, Newell Brands Interim CEO and CFO. "Encouraging first half results and the green shoots of progress we are driving across the business give us the confidence to reiterate our outlook for full year core sales, operating margin and earnings per share and to raise our full year outlook for operating cash flow to between $600 and $800 million. While still early in the organization's turnaround, we believe our decisive and strategic actions to strengthen our performance will drive further improvement going forward, as we work to transform Newell Brands into a leading next-generation consumer products company."

06:37 EDT Essent Group declares inaugural quarterly dividend of 15c per share - The dividend is payable on September 16 to shareholders of record on September 4.

06:32 EDT Restaurant Brands renews $300M NCIB - Restaurant Brands International announced that it has filed, and the Toronto Stock Exchange has accepted, notice of RBI's intention to renew its normal course issuer bid, or NCIB, for its common shares. The NCIB is being conducted in furtherance of RBI's current share repurchase authorization by the board of RBI in August, 2016, pursuant to which RBI may purchase up to $300M of its Common Shares over the next two years. RBI believes that the market price of Common Shares could be such that their purchase may be an attractive and appropriate use of corporate funds.

06:26 EDT RBS announces special dividend of 12p per share - The 2018 final and special dividends recommended were approved by shareholders at the Annual General Meeting on April 25 and the payment made on April 30 to shareholders on the register at the close of business on March 22. RBS announces an interim dividend for 2019 of GBP 241 million, or 2p per ordinary share. In addition, the company announces a further special dividend of GBP 1,449 million, or 12p per ordinary share. The interim and special dividends will be paid on September 20 to shareholders on the register at close of business on August 16. The ex-dividend date will be August 15.

06:24 EDT RBS backs guidance provided in 2018 Annual Results - RBS said: "We retain the outlook we provided in the 2018 Annual Report and Accounts. We anticipate a further GBP 1.2 billion of FX recycling gains in H2 2019 upon the transfer of ownership of NWM N.V. to NWM Plc, subject to regulatory approval, which is capital and TNAV neutral."

06:13 EDT Dentsply Sirona sees FY19 internal sales growth of 4%-5% - FY19 outlook: Portfolio shaping initiatives and M&A reduce 2019 revenues by approximately $60M. At current exchange rates, currency is anticipated to be a 2.5% headwind to 2019 revenues, reducing 2019 reported revenues by approximately $100M. Adjusted operating income margin of 18% to 19%, up from previous adjusted operating margin guidance of 17% to 18%. Operating expenses below 2018 levels. Non-US GAAP effective tax rate of 24.75%, up from previous guidance of 24.0%. 2019 guidance does not incorporate any additional 2019 share repurchase activity.

06:10 EDT Dentsply Sirona CEO says new product lineup 'to drive continued growth' in 2H19 - Don Casey, CEO, commented, "It was a solid quarter as we continue to deliver on the core elements of our restructuring plan of growth, margin improvement and organization simplification. Second quarter internal growth of three percent is in line with the target we outlined last November. Our new product lineup is set to drive continued growth in the back half of the year. We are operating in our new simplified structure that is improving efficiency and enabling us to achieve approximately a one thousand reduction in headcount over the past eight months. In the second quarter, gross margin improved 130 basis points compared to prior year, and our adjusted operating income margin expanded to over 20%. Our results demonstrate that solid sales growth and disciplined expense management drive significant operating leverage. As a result of the robust financial performance in the quarter, today we are increasing our Adjusted EPS guidance for 2019."

06:08 EDT Dentsply Sirona raises quarterly dividend 14% to 10c per share - Payable on October 11th to holders of record at the close of business on September 27th.

06:06 EDT Genesis Energy's Genesis Alkali raises soda ash prices - Genesis Energy's Genesis Alkali business announced that, effective immediately or as contract terms permit, it will increase off-list and list prices for all grades of bulk and packaged soda ash by $15.00 per short ton in the United States and Canada. Genesis Alkali's current energy surcharge program and freight policies remain in effect.

06:05 EDT Google to let Android users in Europe choose default search engine - Google will let Android device users in Europe choose their default search engine from four options, including Google search, following the European Commission's July 2018 Android decision, the company said. New Android smartphones and tablets shipped in the European Economic Area will host a "choice screen" displaying four search engines that users can select from, beginning early 2020, Google said in a blog post. The choice screen will appear during initial device setup and will feature multiple search providers, including Google, it said. Reference Link

05:39 EDT Campbell Soup sells Arnott's, certain international operations to KKR for $2.2B - Campbell Soup (CPB) announced that it has signed a definitive agreement for the sale of Arnott's and certain of Campbell's International operations to KKR (KKR) for $2.2B in cash, subject to customary purchase price adjustments. Combined with the previously disclosed sale of Kelsen Group, Campbell has announced the sale of its entire Campbell International division for an aggregate price of $2.5B. "Acquired by Campbell in 1997, Arnott's is one of Australia's most iconic brands. Arnott's regional headquarters are based in Sydney with operations in Western Sydney, Brisbane, Adelaide and Bekasi, Indonesia. Campbell's International operations include Campbell's simple meals businesses in Australia, Malaysia, Hong Kong and Japan, and manufacturing in Australia and Malaysia. Arnott's and Campbell's International operations had combined net sales of approximately $885M in the latest 12 months and employ approximately 3,800 people." Under the terms of the agreement, Campbell and KKR will enter into a long-term licensing arrangement for the exclusive rights to use certain Campbell brands, including Campbell's, Swanson, V8, Prego, Chunky and Campbell's Real Stock, in Australia, New Zealand, Malaysia and other select markets in Asia, Europe, the Middle East and Africa. Closing for Arnott's and Campbell's International operations, as well as Kelsen Group, is expected in the first half of fiscal 2020.

05:37 EDT Maxar Technologies appoints Carolyn Pittman as Chief Accounting Officer - Maxar Technologies (MAXR) announced the appointment of Carolyn Pittman as Senior Vice President and Chief Accounting Officer, effective July 29. She will become the Company's Principal Accounting Officer, effective August 7. Pittman joins after a 23-year career at Northrop Grumman (NOC) and its spin-off company, Huntington Ingalls (HII), where she held numerous financial leadership positions, including CFO and Vice President Finance and Controller of Newport News Shipbuilding.